Jens Juul Holst and Joel Habener began research on the GLP-1 hormone, initially in relation to duodenal ulcer disease.
Michael Nauck manages to infuse GLP-1 into people with type 2 diabetes, stimulating insulin while inhibiting glucagon and bringing blood glucose to normal levels. However, patients had significant side effects
Semaglutide is created by Novo Nordisk, a global healthcare company headquartered in Denmark that specializes in diabetes care.
Pivotal clinical trials demonstrate the efficacy of semaglutide for type 2 diabetes.
Novo Nordisk submits a New Drug Application (NDA) for semaglutide to the Food and Drug Administration (FDA).
The FDA approves Ozempic (semaglutide) for type 2 diabetes.
The FDA approves Rybelsus, the oral form of semaglutide, for type 2 diabetes.
The FDA approves Wegovy (semaglutide) for chronic weight management.
Novo Nordisk files patents related to semaglutide.
The FDA approves Tirzepatide for weight loss.
Oprah dedicates an entire episode to semaglutide, fueling its popularity.
The artest Kendric Lamar drops "Euphoria", a six-minute diss track in which he publicly accuses Drake of using Ozempic for weight loss.
South Park releases a special 45-minute episode called "South Park: The End of Obesity", highlighting Ozempic's popularity to comedic effect.